Foghorn Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| FOGHORN THERAPEUTICS INC. | ||
| Date: March 11, 2026 | By: | /s/ Ryan Maynard |
|---|---|---|
| Ryan Maynard | ||
| Chief Financial Officer(Principal Accounting and Financial Officer) | ||
SIGNATURES AND POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Adrian Gottschalk and Ryan Maynard, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Adrian Gottschalk | President, Chief Executive Officer and Director(Principal Executive Officer) | March 11, 2026 |
| Adrian Gottschalk | ||
| /s/ Ryan Maynard | Chief Financial Officer(Principal Accounting and Financial Officer) | March 11, 2026 |
| Ryan Maynard | ||
| /s/ Scott Biller | Director | March 11, 2026 |
| Scott Biller, Ph.D. | ||
| Director | March 11, 2026 | |
| Douglas Cole, M.D. | ||
| /s/ Stuart Duty | Director | March 11, 2026 |
| Stuart Duty | ||
| /s/ Neil Gallagher | Director | March 11, 2026 |
| Neil Gallagher, M.D., Ph.D. | ||
| /s/ Simba Gill | Director | March 11, 2026 |
| Simba Gill, Ph.D. | ||
| /s/ Thomas Lynch Jr. | Director | March 11, 2026 |
| Thomas Lynch Jr., M.D. | ||
| /s/ Michael Mendelsohn | Director | March 11, 2026 |
| Michael Mendelsohn, M.D. | ||
| /s/ B. Lynne Parshall | Director | March 11, 2026 |
| B. Lynne Parshall, Esq. | ||
| /s/ Ian Smith | Director | March 11, 2026 |
| Ian Smith | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.